<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02580552</url>
  </required_header>
  <id_info>
    <org_study_id>MRG106-11-101</org_study_id>
    <nct_id>NCT02580552</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL</brief_title>
  <official_title>A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>miRagen Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>miRagen Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives of this clinical trial are to evaluate the safety, tolerability, pharmacokinetics
      and potential efficacy of the investigational drug, MRG-106, in patients diagnosed with
      certain lymphomas and leukemias, including cutaneous T-cell lymphoma (CTCL) [mycosis
      fungoides (MF) subtype], chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma
      (DLBCL), and adult T-cell leukemia/lymphoma (ATLL). MRG-106 is an inhibitor of a molecule
      called miR-155 that is found at high levels in these types of cancers and may be important in
      promoting the growth and survival of the cancer cells. Participants in the clinical trial
      will receive weekly doses of MRG-106 administered by injection under the skin or into a vein,
      or by injection directly into cancerous lesions in the skin (for CTCL only). Blood samples
      will be collected to measure how MRG-106 is processed by the body, and other measurements
      will be performed to study how normal and cancerous cells of the immune system respond when
      exposed to MRG-106.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:

        -  Part A: Cohorts of 3-6 patients diagnosed with MF will receive up to five intratumoral
           injections of MRG-106 over a period of up to 15 days with follow-up for an additional 20
           days, beginning with the maximum deliverable intratumoral dose. Doses may be decreased
           in subsequent cohorts to determine the minimum pharmacodynamically active dose.

        -  Parts B-F: Patients in these parts of the study will be diagnosed with MF (Parts B and
           C), CLL (Part D), DLBCL (Part E), or ATLL (Part F). All patients will receive
           subcutaneous or intravenous MRG-106 (or a combination of systemic and intratumoral
           administration for MF patients only) on Days 1, 3 and 5, and will continue dosing on a
           weekly schedule until the patient becomes intolerant, develops clinically significant
           side effects, progresses, or the trial is terminated. Doses administered will not exceed
           a dose level predicted to be safe based on all prior treatment experience with the drug.
           Patients in Part B may continue on a stable background therapy for their disease during
           their treatment with MRG-106, while patients in Parts C-F will be treated with MRG-106
           alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of MRG-106 based on vital signs, physical examination, clinical laboratory tests, ECG, and incidence and severity of adverse events</measure>
    <time_frame>From start of treatment to end of study participation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration vs. time curve (AUC) of MRG-106 following single and repeat doses administered intratumorally, subcutaneously or intravenously</measure>
    <time_frame>Up to 56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) of MRG-106 following single and repeat doses administered intratumorally, subcutaneously or intravenously</measure>
    <time_frame>Up to 56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentration (Ctrough) of MRG-106 following each 4-week cycle of dosing</measure>
    <time_frame>Monthly from Week 5 up to end of study participation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin disease severity (index lesions) - MF only</measure>
    <time_frame>Every 2 weeks from start of treatment until end of study participation</time_frame>
    <description>Changes in MF skin lesion severity before and after treatment based on the Composite Assessment of Index Lesion Severity (CAILS) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin disease severity (whole body) - MF only</measure>
    <time_frame>Every 2 weeks from start of treatment until end of study participation</time_frame>
    <description>Changes in MF skin lesion severity before and after treatment based on the modified Severity Weighted Assessment Tool (mSWAT) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate - MF</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Proportion of subjects who achieve a partial response (PR) or complete response (CR) as defined by international consensus criteria (Olsen et al., 2011), based on SWAT score and confirmed by computed tomography (CT) scan and flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate - CLL</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Proportion of subjects who achieve a PR or CR as defined by IWCLL criteria (Hallek et al., 2008) based on CT scans, bone marrow biopsies, and flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Residual Disease (MRD) - CLL only</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Proportion of subjects who achieve a CR with no evidence of MRD by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate - DLBCL</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Proportion of subjects who achieve a PR or CR as defined by the Lugano classification (Cheson et al., 2014) based on positron emission tomography-computed tomography (PET-CT) scans and bone marrow biopsy to confirm CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate - ATLL</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Proportion of subjects who achieve a PR or CR as defined by international consensus criteria (Tsukasaki et al., 2008) based on CT scans and flow cytometry, and bone marrow biopsy to confirm CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Number of days from initial date of confirmed PR or CR until loss of response or relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Number of days from first dose until objective disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Number of days from first dose until objective disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Number of days from first dose until death from any cause</description>
  </secondary_outcome>
  <other_outcome>
    <measure>miR-155-5p expression in cutaneous lesions of subjects with MF</measure>
    <time_frame>At baseline and between Week 16 and end of study participation</time_frame>
    <description>Exploratory assessment based on quantitative real time polymerase chain reaction (qRT-PCR) analysis of total RNA isolated from skin biopsies</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of CD4+ cells in cutaneous lesions of subjects with MF</measure>
    <time_frame>At baseline and between Week 16 and end of study participation</time_frame>
    <description>Exploratory histological assessment before and after treatment with MRG-106</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportions of immune cell subsets</measure>
    <time_frame>At baseline and monthly or bimonthly, up to end of study participation</time_frame>
    <description>Exploratory assessment before and after treatment with MRG-106 by flow cytometry on whole blood</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Cutaneous T-cell Lymphoma (CTCL)</condition>
  <condition>Mycosis Fungoides (MF)</condition>
  <condition>Chronic Lymphocytic Leukemia (CLL)</condition>
  <condition>Diffuse Large B-Cell Lymphoma (DLBCL)</condition>
  <condition>Adult T-Cell Leukemia/Lymphoma (ATLL)</condition>
  <arm_group>
    <arm_group_label>Part A, MF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumoral Injection of MRG-106</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, MF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous, intravenous or a combination of systemic and intratumoral administration of MRG-106 with stable background therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C, MF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous or intravenous administration of MRG-106 as monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D, CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous or intravenous administration of MRG-106 as monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part E, DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous or intravenous administration of MRG-106 as monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part F, ATLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous or intravenous administration of MRG-106 as monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRG-106</intervention_name>
    <arm_group_label>Part A, MF</arm_group_label>
    <arm_group_label>Part B, MF</arm_group_label>
    <arm_group_label>Part C, MF</arm_group_label>
    <arm_group_label>Part D, CLL</arm_group_label>
    <arm_group_label>Part E, DLBCL</arm_group_label>
    <arm_group_label>Part F, ATLL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parts A-C only: Patients must have biopsy proven MF, clinical stage I, II, or III
             (excluding visceral or nodal involvement), and must be refractory to or intolerant of
             established therapies for their condition

          -  Part D only: Patients diagnosed with CLL who are intolerant to, or have disease that
             is relapsed/refractory after, at least two prior therapies

          -  Part E only: Patients with biopsy-proven DLBCL who are intolerant to, or have disease
             that is relapsed/refractory after, at least two prior therapies, including any
             anti-CD20 monoclonal antibody and chemotherapy with curative intent

          -  Part F only: Patients with documented HTLV-1 infection and histologically or
             cytologically proven ATLL of any stage, and who are intolerant to, or have disease
             that is relapsed/refractory after, at least one prior therapy

          -  Females must not be pregnant or lactating. Women of child-bearing potential must use a
             highly effective method of contraception throughout their study participation and for
             at least 6 months following the last dose of study drug.

          -  Males must be surgically sterile, abstinent, or if engaged in sexual relations with a
             female of child-bearing potential, must be willing to use a highly effective method of
             contraception throughout their study participation and for at least 6 months after the
             last dose of study drug.

        Exclusion Criteria:

          -  Evidence of renal or liver dysfunction at screening

          -  Clinically significant anemia, neutropenia or thrombocytopenia at screening

          -  History of bleeding diathesis or coagulopathy

          -  Clinically significant cardiovascular disease, history of myocardial infarction within
             the last 6 months, or evidence of QTc interval prolongation at screening

          -  Serologically positive for HIV; serologically positive for Hepatitis B or Hepatitis C
             with evidence of liver dysfunction or documented liver cirrhosis

          -  Prior malignancies within the past 3 years (with allowance for adequately treated in
             situ carcinoma of the cervix uteri, and basal cell or localized squamous cell
             carcinoma of the skin treated with curative intent)

          -  Use of an investigational small molecule drug during the 30 days prior to screening or
             use of an investigational oligonucleotide or biologic drug during the prior 90 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Rubin, MD</last_name>
    <role>Study Director</role>
    <affiliation>miRagen Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>miRagen Therapeutics, Inc.</last_name>
    <phone>720-407-4603</phone>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaemee Bautista</last_name>
      <phone>626-218-3033</phone>
      <email>jbautista@coh.org</email>
    </contact>
    <investigator>
      <last_name>Christiane Querfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie McCarthy, MA</last_name>
      <phone>858-822-0743</phone>
      <email>nmccarthy@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Kipps, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Department of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonsson Comprehensive Cancer Center Clinical Research Unit</last_name>
      <phone>310-794-6500</phone>
    </contact>
    <investigator>
      <last_name>Herbert Eradat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center at University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>877-827-8839</phone>
      <email>ucstudy@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Lauren Pinter-Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zachary Hopkins</last_name>
      <phone>650-421-6370</phone>
      <email>zehop@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Youn Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado, Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachael Wax</last_name>
      <phone>720-848-9384</phone>
      <email>rachael.wax@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Theresa R. Pacheco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale-New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Leary</last_name>
      <phone>203-737-8884</phone>
      <email>laura.leary@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Francine Foss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University; Department of Dermatology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Serrano</last_name>
      <phone>312-503-5900</phone>
      <email>linda.serrano@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Joan Guitart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alison Moskowitz, MD</last_name>
      <phone>212-639-4839</phone>
      <email>moskoia@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Alison Moskowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliana Engleman</last_name>
      <phone>614-685-6005</phone>
      <email>Juliana.Engleman@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Basem William, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophia Hines</last_name>
      <phone>215-955-0030</phone>
      <email>Sophia.hines@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Pierluigi Porcu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Arriaga</last_name>
      <phone>713-794-1447</phone>
      <email>larriaga@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Auris Huen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmad Halwani, MD</last_name>
      <phone>801-581-4477</phone>
      <email>clinical.trials@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Ahmad Halwani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Melanoma and Skin Cancer Center / Inova Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Jeffords, CCRC, CCRP</last_name>
      <phone>703-208-6606</phone>
      <email>kelly.jeffords@inova.org</email>
    </contact>
    <investigator>
      <last_name>Jennifer DeSimone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>van Kester MS, Ballabio E, Benner MF, Chen XH, Saunders NJ, van der Fits L, van Doorn R, Vermeer MH, Willemze R, Tensen CP, Lawrie CH. miRNA expression profiling of mycosis fungoides. Mol Oncol. 2011 Jun;5(3):273-80. doi: 10.1016/j.molonc.2011.02.003. Epub 2011 Feb 24.</citation>
    <PMID>21406335</PMID>
  </reference>
  <reference>
    <citation>Moyal L, Barzilai A, Gorovitz B, Hirshberg A, Amariglio N, Jacob-Hirsch J, Maron L, Feinmesser M, Hodak E. miR-155 is involved in tumor progression of mycosis fungoides. Exp Dermatol. 2013 Jun;22(6):431-3. doi: 10.1111/exd.12161.</citation>
    <PMID>23711069</PMID>
  </reference>
  <reference>
    <citation>Maj J, Jankowska-Konsur A, Sadakierska-Chudy A, Noga L, Reich A. Altered microRNA expression in mycosis fungoides. Br J Dermatol. 2012 Feb;166(2):331-6. doi: 10.1111/j.1365-2133.2011.10669.x. Epub 2012 Jan 9.</citation>
    <PMID>21966986</PMID>
  </reference>
  <reference>
    <citation>Kopp KL, Ralfkiaer U, Gjerdrum LM, Helvad R, Pedersen IH, Litman T, Jønson L, Hagedorn PH, Krejsgaard T, Gniadecki R, Bonefeld CM, Skov L, Geisler C, Wasik MA, Ralfkiaer E, Ødum N, Woetmann A. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle. 2013 Jun 15;12(12):1939-47. doi: 10.4161/cc.24987. Epub 2013 May 15.</citation>
    <PMID>23676217</PMID>
  </reference>
  <reference>
    <citation>Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E, Dahlberg JE. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32. Epub 2005 Feb 28.</citation>
    <PMID>15738415</PMID>
  </reference>
  <reference>
    <citation>Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J, Ghia EM, Zhang L, Bao L, Rassenti LZ, Messer K, Calin GA, Croce CM, Kipps TJ. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014 Jul 24;124(4):546-54. doi: 10.1182/blood-2014-03-559690. Epub 2014 Jun 9.</citation>
    <PMID>24914134</PMID>
  </reference>
  <reference>
    <citation>Guinn D, Ruppert AS, Maddocks K, Jaglowski S, Gordon A, Lin TS, Larson R, Marcucci G, Hertlein E, Woyach J, Johnson AJ, Byrd JC. miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. Leukemia. 2015 May;29(5):1210-3. doi: 10.1038/leu.2014.344. Epub 2014 Dec 9.</citation>
    <PMID>25486872</PMID>
  </reference>
  <reference>
    <citation>Tomita M. Important Roles of Cellular MicroRNA miR-155 in Leukemogenesis by Human T-Cell Leukemia Virus Type 1 Infection. ISRN Microbiol. 2012 Sep 18;2012:978607. doi: 10.5402/2012/978607. Print 2012.</citation>
    <PMID>23762762</PMID>
  </reference>
  <reference>
    <citation>Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC; International Society for Cutaneous Lymphomas; United States Cutaneous Lymphoma Consortium; Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011 Jun 20;29(18):2598-607. doi: 10.1200/JCO.2010.32.0630. Epub 2011 May 16.</citation>
    <PMID>21576639</PMID>
  </reference>
  <reference>
    <citation>Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 Jun 15;111(12):5446-56. doi: 10.1182/blood-2007-06-093906. Epub 2008 Jan 23. Erratum in: Blood. 2008 Dec 15;112(13):5259.</citation>
    <PMID>18216293</PMID>
  </reference>
  <reference>
    <citation>Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059-68.</citation>
    <PMID>25113753</PMID>
  </reference>
  <reference>
    <citation>Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, O'Mahony D, Janik JE, Bittencourt AL, Taylor GP, Yamaguchi K, Utsunomiya A, Tobinai K, Watanabe T. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009 Jan 20;27(3):453-9. doi: 10.1200/JCO.2008.18.2428. Epub 2008 Dec 8.</citation>
    <PMID>19064971</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cutaneous T-cell Lymphoma</keyword>
  <keyword>CTCL</keyword>
  <keyword>Mycosis Fungoides</keyword>
  <keyword>Chronic lymphocytic leukemia</keyword>
  <keyword>CLL</keyword>
  <keyword>Diffuse large B-cell lymphoma</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Adult T-cell leukemia/lymphoma</keyword>
  <keyword>ATLL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

